What Uni-Bio Sciences does

Uni-Bio Science Group Limited (Hong Kong Stock Exchange: 00690.HK) is a biopharmaceutical company founded in 2001, headquartered in Hong Kong with three GMP-certified manufacturing bases in Beijing, Dongguan, and Shenzhen. The company employs 501-1,000 people and operates across four regenerative medicine verticals: muscular-skeletal, skin regeneration, ophthalmology, and ENT. Its commercialized portfolio spans biopharmaceuticals (Bogutai®/Teriparatide Injection for osteoporosis, GeneTime®/hEGF for wound healing, GeneSoft® for ophthalmology, Diquafosol Sodium Eye Drops/Jinyinkang®), high-value generics (Pinup®/Acarbose, Boshutai®), and medical aesthetics (GeneQueens®, Jinyinfu®, Jiyan Tai®). The company serves Chinese tier 1-4 hospital networks, pharmacies, e-commerce consumers, and emerging international markets via distribution partnerships.

The company's R&D infrastructure rests on two proprietary technology platforms: the ECO-KSFA® Microprotein Superfactory, which integrates gene editing, AI-driven strain screening, vesicle-mediated nucleopeptide secretion, and continuous fermentation to enable kilogram-scale production of structurally complex mini-proteins; and the Smart Responsive Hydrogel Technology Platform, which uses polymeric materials and responsive matrices for tissue engineering applications including self-healing, controlled drug release, and stem cell integration. Uni-Bio holds 110+ authorized patents, has 4 pipeline assets (UB107 BMP-2 bone regeneration device, UB106 obesity antibody, Uni-PTH microneedle, Isavuconazonium Sulfate antifungal), and operates an integrated value chain spanning target discovery through commercial manufacturing.

Uni-Bio generates revenue through direct product sales across hospital networks (omni-channel field sales covering tier 1-4 markets), pharmacy distributors, e-commerce platforms, and emerging licensing/partnership arrangements. In 2025, the company reported HK$586.2 million in revenue (+6.0% YoY) and HK$93.3 million in net profit (+12.7% YoY), translating to a 15.9% net margin and a HK$1.56-cent EPS. Bogutai® alone delivered HK$134 million (111% YoY growth) since its March 2024 launch. International expansion is structured around the September 2025 Kexing Biopharm partnership for Bogutai® in six emerging markets (Saudi Arabia, Egypt, Morocco, Colombia, Argentina, Mexico) and a direct FDA application for the US market expected by 2027. December 2025 marked a strategic repositioning from 'Stable Growth' to 'Innovation-Driven', targeting global regenerative medicine leadership across the four therapeutic verticals.

Name

Uni-Bio Sciences

Legal name

联康生物科技集团有限公司

Website

https://uni-bioscience.com

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Uni-Bio Science Group is a Hong Kong-listed biopharmaceutical company developing regenerative medicines for osteoporosis, skin wounds, dry eye, and ENT conditions, leveraging proprietary ECO-KSFA® peptide and smart hydrogel platforms with three GMP manufacturing bases in China.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Ophthalmology Pharmaceuticals (HLAIAAAL), Dermatology Specialty Pharmaceuticals (HLAIACAL), Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

• Regenerative medicine biopharmaceuticals
• Osteoporosis treatment drugs
• Growth factor therapeutics
• Ophthalmic pharmaceuticals
• Medical aesthetics devices

Headquarters

HQ city

Central

HQ country

Hong Kong SAR China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Product Sales - Biopharmaceuticals: Direct sales of proprietary and licensed pharmaceutical products including Bogutai® (Teriparatide Injection), GeneTime®, GeneSoft®, and other biopharmaceuticals through hospital networks, pharmacies, and e-commerce platforms
2. Product Sales - Generics: Sales of high-value generic drugs including Pinup® (acarbose), Boshutai® (benfotiamine), and other established pharmaceutical products through volume-based procurement and hospital channels
3. Product Sales - Medical Aesthetics: Sales of medical aesthetics products including GeneQueens®, Jinyinfu®, and other skincare/medical device products through professional channels and consumer retail
4. International Licensing/Partnership Revenue: Licensing revenue from international partnerships such as Kexing Biopharm collaboration for Bogutai® commercialization in six international markets, with revenue expected from late 2026

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

Uni-Bio Sciences researches, develops, manufactures, and commercializes proprietary biopharmaceutical products for regenerative medicine, including prescription therapies for osteoporosis (Bogutai Teriparatide Injection), wound healing and skin regeneration (GeneTime hEGF), ophthalmic conditions (GeneSoft, Jinyinkang Diquafosol Sodium Eye Drops), and a medical aesthetics portfolio (GeneQueens, Jinyinfu). Products are manufactured at three GMP-certified facilities in Beijing, Dongguan, and Shenzhen, and sold through hospital networks, pharmacies, e-commerce, and international licensing partners.

Product overview

Uni-Bio Science Group is a biopharmaceutical company that has evolved from an integrated pharmaceutical company into a global leader in regenerative medicine. The portfolio consists of three main pillars: (1) Biopharmaceuticals including Bogutai (Teriparatide Injection) for osteoporosis, GeneTime/GeneSoft for wound healing and eye care, and 金因康 for dry eye treatment; (2) Medical aesthetics encompassing the 肌颜态 brand with GeneQueens premium skincare and 金因敷 medical device products; and (3) High-value generics including Pinup (Acarbose) and Boshutai. The company operates two core technology platforms—ECO-KSFA Microprotein Superfactory for complex peptide production and Smart Responsive Hydrogel for tissue engineering—and is developing pipeline products including UB107 (bone regeneration), UB106 (obesity treatment), and Uni-PTH microneedle formulation. The company has GMP manufacturing bases in Beijing, Dongguan, and Shenzhen, serving the complete value chain from R&D through commercialization.

Differentiator

Problem solved

Functional benefit

Brands

• Bogutai (博固泰): Teriparatide Injection - recombinant human parathyroid hormone analog (PTH1-34) for osteoporosis treatment approved in China in January 2024
• GeneTime (金因肽)
• GeneSoft (金因舒)
• 金因康 (Diquafosol Sodium Eye Drops)
• GeneQueens (肌颜态高端系列)
• 金因敷
• Pinup (匹纳普)
• Boshutai (博舒泰)
• 肌颜态

Products and services

• Bogutai (博固泰) Teriparatide Injection
• GeneTime (金因肽)
• GeneSoft (金因舒)
• Jinyinkang (金因康) Diquafosol Sodium Eye Drops
• Pinup (匹纳普) Acarbose Tablets
• Boshutai (博舒泰)
• GeneQueens (肌颜态高端系列)
• Jinyinfu (金因敷)
• Jiyantai (肌颜态) Medical Aesthetics Brand

Quantifiable outcome

• Bogutai® revenue increased 248.9% YoY to HK$65.6 million in H1 2025
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

14 partnerships are on record, tiered core and minor.

• Wenzhou Medical University National Engineering Research Center (温医大国家工程研究中心)coreStrategic or Co-development Partner · 30 December 2025Tripartite strategic cooperation with WMU NERC and Ouhai District Government to build growth factor innovation ecosystem. Plans include establishment of Uni-Bio-WMU Joint Innovation Laboratory for Translational Medicine to explore EGF/FGF combined therapies for burns, dermatology, and ophthalmology. The Center, led by Academician Li Xiaokun, is a global leader in FGF drug R&D.
• Ouhai District Government, Wenzhou (瓯海区政府)coreStrategic or Co-development Partner · 30 December 2025Government partner in tripartite strategic cooperation providing policy support, China Gene Valley platform for R&D, pilot testing, and industrialization. The government provides comprehensive spatial support and specialized policy assistance for the cooperative projects.
• Kexing Biopharm (科兴制药)coreChannel Partner/ Reseller/ Distributor · 12 September 2025Strategic partnership granting Kexing Biopharm exclusive commercialization rights for Bogutai® (Teriparatide Injection) in six international markets: Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. Kexing brings over 20 years of international commercialization experience and established marketing network spanning EU and emerging markets. Revenue expected from cooperation regions as early as end of 2026.
• Global Cosmetics Group (高宝化妆品集团)minorStrategic or Co-development Partner · 27 June 2025Strategic partnership to establish medical research co-creation biological platform. Jointly developed Skbrella FN (皮优理) - a highly bioactive recombinant human fibronectin using gene-editing biosynthesis technology for medical aesthetics applications.
• Medical Aesthetics Chain Institutions and Regional DistributorsminorChannel Partner/ Reseller/ Distributor · 27 June 2025Distribution partnerships with well-known medical aesthetics chain institutions and regional agents for commercialization of GeneQueens® and Jinyinfu® products. Strategic signing ceremony held at Changsha launch event.
• Dawan Bio (大湾生物) and TigerMed's Pebble Accelerator (泰格医药)minorStrategic or Co-development Partner · 1 May 2024Joint development of innovative weight loss drug. Partnership aims to establish comprehensive ecosystem from target discovery to antibody generation, drug feasibility verification, process development, clinical pipeline, and commercialization.
• Chongqing Minji Medical Devices (重庆民济医疗器械有限公司)minorStrategic or Co-development Partner · 1 January 2024Joint development of recombinant collagen dressing medical device products. Collaboration resulted in Class II medical device approval and launch of skin repair products.
• Global GroupminorStrategic or Co-development Partner · 1 January 2024Partnership for aesthetic medicine products development, marking early entry into medical aesthetics sector.
• DotBiominorStrategic or Co-development Partner · 1 January 2021Strategic cooperation for Dot Body development in the field of innovative biologics.
• Alephoson BiopharmaceuticalminorStrategic or Co-development Partner · 1 January 2021Strategic cooperation for development of macular degeneration eye drops utilizing anti-VEGF technology.
• Southern Medical University Dermatology Hospital Cosmetics Testing CenterminorStrategic or Co-development Partner · 1 January 2021Joint clinical research on fibronectin efficacy in skin barrier repair post-medical procedures. Research presented at CSD2025 academic conference.
• YpsomedminorStrategic or Co-development Partner · 1 January 2020Co-development of next-generation products, potentially including Uni-PTH microneedle formulation.
• Medlink (麦迪领)minorChannel Partner/ Reseller/ Distributor · 1 January 2020Strategic alliance for e-commerce advancement and digital distribution of pharmaceutical products.
• Sinopharm Weiqida (国药威奇达) and Suzhou Yingli (苏州亿利)minorStrategic or Co-development Partner · 1 January 2020Strategic collaboration for Acarbose development, expanding diabetes treatment portfolio.

Scale indicators16 records

Recent moves8 records

Expansion highlights6 records

Others

• Ypsomed: Swiss medical device company specializing in injection systems and microneedle platforms; comparable as a co-development partner to Uni-Bio for Uni-PTH microneedle formulation, with overlapping drug-delivery technology expertise.
• Tigermed: China's largest clinical CRO with extensive biopharma services; relevant as a clinical and R&D infrastructure partner ecosystem to which Uni-Bio's pipeline assets (UB106, UB107, Uni-PTH microneedle) are connected through the broader Chinese biotech value chain.

Broad incumbents

• Luye Pharma Group: Hong Kong-listed Chinese pharma with biologics, oncology, and specialty care franchises plus international commercialization capabilities; comparable scale and product breadth to Uni-Bio's broader regenerative medicine vision.
• Sino Biopharmaceutical: One of the largest Chinese pharmaceutical conglomerates with broad specialty, biotech, and innovative drug operations; provides an incumbent benchmark for Uni-Bio's long-term aspirations of becoming a major Chinese biopharma.
• Hansoh Pharmaceutical: Large established Chinese innovative pharma with biologics and specialty care portfolio; broader and more diversified than Uni-Bio but competes in overlapping specialty areas including endocrine and oncology-adjacent indications.

Direct peers

• Shanghai Henlius Biotech: Hong Kong-listed Chinese biotech focused on biosimilars and innovative biologics across oncology and chronic disease; comparably positioned as a Chinese biosimilar/innovator with manufacturing scale and NMPA approval cadence akin to Uni-Bio's pipeline rhythm.
• Bloomage Biotechnology: Leading Chinese biotech focused on hyaluronic acid and bioactive ingredients for skin/medical aesthetics; directly overlaps Uni-Bio's medical aesthetics business (GeneQueens®, Jinyinfu®, Skbrella FN) targeting dermatology and post-procedure repair.
• Hutchmed (HUTCHMED): Hong Kong- and Nasdaq-listed Chinese innovative biotech with global drug development capability; directly comparable as a smaller-cap Hong Kong-listed Chinese biotech pursuing international regulatory pathways similar to Uni-Bio's FDA play for Bogutai®.
• Innovent Biologics: Hong Kong-listed Chinese innovator biotech commercializing innovative biologics across metabolic and chronic disease indications; comparable in biologics platform and Chinese commercialization footprint to Uni-Bio's specialty biopharmaceutical portfolio.
• 3SBio: Major Chinese biopharmaceutical company with biosimilars and biologics franchises including teriparatide competition for osteoporosis; overlapping regenerative and specialty biologics product portfolio most directly comparable to Uni-Bio's Bogutai® franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/search/results/all/?fetchDeterministicClustersOnly=true&heroEntityKey=urn%3Ali%3Aorganization%3A3637076&keywords=uni-bio%20science%20group%20(hk690)%20%E8%81%94%E5%BA%B7%E7%94%9F%E7%89%A9%E7%A7%91%E6%8A%80%E9%9B%86%E5%9B%A2&origin=RICH_QUERY_SUGGESTION&position=0&searchId=baa7ff0b-82e3-4dea-879b-e0bb98b056c4&sid=XId&spellCorrectionEnabled=false
• Xx.com/Uni_Bio_Science
• Facebookfacebook.com/unibioscience

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles23 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Uni-Bio Sciences